Global Acquired Angioedema Treatment Market, By Type (Type 1, Type 2), Treatment (Icatibant, Rituximab, Ecallantide, Corticosteroids, Antihistamines, Fresh Frozen Plasma(FFP), Others), Diagnosis (Testing C1-INH and C4, MRI, CT scan, Autoantibody Test, Laboratory Tests, Others), Dosage (Tablet, Injection, Solution, Others), Route of Administration (Oral, Subcutaneous, Intramuscular, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Global Acquired Angioedema Treatment Market
Acquired angioedema treatment market is expected to gain market growth in the forecast period of 2021-2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 4.80% in the above mentioned forecast period.
Acquired angioedema is a rare disorder which is characterised by edema. It occurs as transitory and recurrent subcutaneous edema and caused due to the deficiency of acquired C1 inhibitor (C1-INH). It further results in the swelling of face, limbs, lips, tongue or genitals and also causes abdominal pain. This condition can be immunologic or non-immunologic and mostly caused due to the allergy. It also appears together with urticarial and other allergic symptoms. It is regularly related with the lymphoproliferative diseases and B-cell malignancies.
Rise in the prevalence of acquired angioedema, growing healthcare expenditure, rise in the geriatric population, surge in the demand for the advanced treatment of acquired angioedema, growing government funding and rising initiatives by government and private organisations to spread awareness about the treatment of rare diseases are the factors that will expand the acquired angioedema treatment market.
Rise in the research and development activities and advancement in the treatment options will provide beneficial opportunities for the acquired angioedema treatment market in the forecast period of 2021-2028.
- On the other hand, the high cost of treatment and side effects associated with the medication are the factors that will hinder the market growth. Lack of awareness about rare diseases and its treatment will challenge the acquired angioedema treatment market in the forecast period mentioned above.
This acquired angioedema treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the acquired angioedema treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Acquired Angioedema Treatment Market Scope and Market Size
The acquired angioedema treatment market is segmented on the basis of type, treatment, diagnosis, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of type, the acquired angioedema treatment market is segmented into type 1 and type 2.
- On the basis of treatment, the acquired angioedema treatment market is segmented into icatibant, ecallantide, corticosteroids, antihistamines, fresh frozen plasma (FFP) and others.
- On the basis of diagnosis, the acquired angioedema treatment market is segmented into testing C1-INH and C4, MRI, CT scan, autoantibody test, laboratory tests and others.
- On the basis of dosage, the acquired angioedema treatment market is segmented into tablet, injection, solution and others.
- On the basis of route of administration, the acquired angioedema treatment market is segmented into oral, subcutaneous, intramuscular and others.
- On the basis of end-users, the acquired angioedema treatment market is segmented into clinic, hospital and others.
The acquired angioedema treatment market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.
Acquired Angioedema Treatment Market Country Level Analysis
Acquired angioedema treatment market is analyzed and market size information is provided by the country, type, treatment, diagnosis, dosage, route of administration, end-users and distribution channel as referenced above.
The countries covered in the acquired angioedema treatment market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.
North America dominates the acquired angioedema treatment market due to the presence of major key players, growing investment for R&D activities, high disposable income, high healthcare expenditure and well-developed healthcare sector in this region. Asia-Pacific is expected to grow during the forecast period of 2021-2028 due to the increasing research and development activities, rising investment in the healthcare sector and growing government support.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Acquired angioedema treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Global Acquired Angioedema Treatment Market Share Analysis
Acquired angioedema treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to acquired angioedema treatment market research.
The major players covered in the acquired angioedema treatment market report are Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Novartis AG, Cipla Inc., AstraZeneca, GlaxoSmithKline plc, Merck Sharp & Dohme Corp., Takeda Pharmaceutical Company Limited, Fresenius Kabi AG, CSL, Pharming Group N.V., BIOCRYST PHARMACEUTICALS, INC., Attune Pharmaceuticals, Ionis Pharmaceuticals, Adverum Biotechnologies, Inc., Johnson & Johnson Private Limited, Baxter, Bayer AG, Merck KGaA, Sun Pharmaceutical Industries Ltd., and Sumitomo Corporation, among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-